Table of Contents Author Guidelines Submit a Manuscript
Oxidative Medicine and Cellular Longevity
Volume 2015, Article ID 391790, 9 pages
http://dx.doi.org/10.1155/2015/391790
Research Article

Oxidative Stress: Dual Pathway Induction in Cardiorenal Syndrome Type 1 Pathogenesis

1Department of Nephrology, Dialysis and Transplant, San Bortolo Hospital, 36100 Vicenza, Italy
2International Renal Research Institute of Vicenza (IRRIV), Italy
3Department of Nephrology and Dialysis, San Giovanni Di Dio Hospital, 92100 Agrigento, Italy
4Department of Medicine DIMED, University of Padua Medical School, 35128 Padua, Italy
5Laboratory of Experimental Hepatology, Department of Medicine, University of Padua, 35128 Padua, Italy
6Department of Information Engineering, University of Padua, 35128 Padua, Italy
7Internal Medicine, San Bortolo Hospital, 36100 Vicenza, Italy
8Internal Medicine Unit, Sant’Antonio Hospital, 35127 Padua, Italy

Received 3 December 2014; Revised 11 February 2015; Accepted 15 February 2015

Academic Editor: Noriko Noguchi

Copyright © 2015 Grazia Maria Virzì et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Clementi, G. M. Virzi, C. Y. Goh et al., “Cardiorenal syndrome type 4: a review,” Cardiorenal Medicine, vol. 3, no. 1, pp. 63–70, 2013. View at Publisher · View at Google Scholar
  2. C. Ronco, C.-Y. Chionh, M. Haapio, N. S. Anavekar, A. House, and R. Bellomo, “The cardiorenal syndrome,” Blood Purification, vol. 27, no. 1, pp. 114–126, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. C. Ronco, M. Cicoira, and P. A. McCullough, “Cardiorenal syndrome type 1: pathophysiological crosstalk leading to combined heart and kidney dysfunction in the setting of acutely decompensated heart failure,” Journal of the American College of Cardiology, vol. 60, no. 12, pp. 1031–1042, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. C. Ronco, M. Haapio, A. A. House, N. Anavekar, and R. Bellomo, “Cardiorenal syndrome,” Journal of the American College of Cardiology, vol. 52, no. 19, pp. 1527–1539, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. G. M. Virzì, S. Day, M. de Cal, G. Vescovo, and C. Ronco, “Heart-kidney crosstalk and role of humoral signaling in critical illness,” Critical Care, vol. 18, no. 1, article 201, 2014. View at Publisher · View at Google Scholar · View at Scopus
  6. G. Viswanathan and S. Gilbert, “The cardiorenal syndrome: making the connection,” International Journal of Nephrology, vol. 2011, Article ID 283137, 10 pages, 2011. View at Publisher · View at Google Scholar
  7. G. R. Kinsey, L. Li, and M. D. Okusa, “Inflammation in acute kidney injury,” Nephron—Experimental Nephrology, vol. 109, no. 4, pp. e102–e107, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. D. W. Lee, S. Faubel, and C. L. Edelstein, “Cytokines in acute kidney injury (AKI),” Clinical Nephrology, vol. 76, no. 3, pp. 165–173, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. D. F. Mangan and S. M. Wahl, “Differential regulation of human monocyte programmed cell death (apoptosis) by chemotactic factors and pro-inflammatory cytokines,” Journal of Immunology, vol. 147, no. 10, pp. 3408–3412, 1991. View at Google Scholar · View at Scopus
  10. M. Murakami and T. Hirano, “The pathological and physiological roles of IL-6 amplifier activation,” International Journal of Biological Sciences, vol. 8, no. 9, pp. 1267–1280, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Nian, P. Lee, N. Khaper, and P. Liu, “Inflammatory cytokines and postmyocardial infarction remodeling,” Circulation Research, vol. 94, no. 12, pp. 1543–1553, 2004. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Satoh, Y. Ishikawa, T. Itoh, Y. Minami, Y. Takahashi, and M. Nakamura, “The expression of TNF-alpha converting enzyme at the site of ruptured plaques in patients with acute myocardial infarction,” European Journal of Clinical Investigation, vol. 38, no. 2, pp. 97–105, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. R. Schindler, O. Boenisch, C. Fischer, and U. Frei, “Effect of the hemodialysis membrane on the inflammatory reaction in vivo,” Clinical Nephrology, vol. 53, no. 6, pp. 452–459, 2000. View at Google Scholar · View at Scopus
  14. G. Torre-Amione, “Immune activation in chronic heart failure,” The American Journal of Cardiology, vol. 95, supplement 1, no. 11, pp. 3–8, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. B. J. Wrigley, G. Y. H. Lip, and E. Shantsila, “The role of monocytes and inflammation in the pathophysiology of heart failure,” European Journal of Heart Failure, vol. 13, no. 11, pp. 1161–1171, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. M. Metra, G. Cotter, M. Gheorghiade, L. D. Cas, and A. A. Voors, “The role of the kidney in heart failure,” European Heart Journal, vol. 33, no. 17, pp. 2135–2142, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Rubattu, S. Mennuni, M. Testa et al., “Pathogenesis of chronic cardiorenal syndrome: is there a role for oxidative stress?” International Journal of Molecular Sciences, vol. 14, no. 11, pp. 23011–23032, 2013. View at Publisher · View at Google Scholar · View at Scopus
  18. N. Hata, S. Yokoyama, T. Shinada et al., “Acute kidney injury and outcomes in acute decompensated heart failure: evaluation of the RIFLE criteria in an acutely ill heart failure population,” European Journal of Heart Failure, vol. 12, no. 1, pp. 32–37, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. K. V. Liang, A. W. Williams, E. L. Greene, and M. M. Redfield, “Acute decompensated heart failure and the cardiorenal syndrome,” Critical Care Medicine, vol. 36, no. 1, supplement, pp. S75–S88, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. C. Ronco, P. A. McCullough, S. D. Anker et al., “Cardiorenal syndromes: an executive summary from the consensus conference of the acute dialysis quality initiative (ADQI),” Contributions to Nephrology, vol. 165, pp. 54–67, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. D. N. Cruz, “Cardiorenal syndrome in critical care: the acute cardiorenal and renocardiac syndromes,” Advances in Chronic Kidney Disease, vol. 20, no. 1, pp. 56–66, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. R. Gill, A. Tsung, and T. Billiar, “Linking oxidative stress to inflammation: toll-like receptors,” Free Radical Biology and Medicine, vol. 48, no. 9, pp. 1121–1132, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. S. R. Khan, “Stress oxidative: nephrolithiasis and chronic kidney diseases,” Minerva Medica, vol. 104, no. 1, pp. 23–30, 2013. View at Google Scholar · View at Scopus
  24. P.-L. Li and Y. Zhang, “Cross talk between ceramide and redox signaling: Implications for endothelial dysfunction and renal disease,” Handbook of Experimental Pharmacology, vol. 216, pp. 171–197, 2013. View at Google Scholar · View at Scopus
  25. C. H. Mandavia, A. R. Aroor, V. G. Demarco, and J. R. Sowers, “Molecular and metabolic mechanisms of cardiac dysfunction in diabetes,” Life Sciences, vol. 92, no. 11, pp. 601–608, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. J. J. McMurray, S. Adamopoulos, S. D. Anker et al., “ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC,” European Journal of Heart Failure, vol. 14, no. 8, pp. 803–869, 2012. View at Publisher · View at Google Scholar
  27. R. L. Mehta, J. A. Kellum, S. V. Shah et al., “Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury,” Critical Care, vol. 11, no. 2, p. R31, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. M. Volpe and G. Toccib, “2007ESH/ESC Guidelines for the management of hypertension, from theory to practice: global cardiovascular risk concept,” Journal of Hypertension, vol. 27, supplement 3, pp. S3–S11, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. D. W. Haslam and W. P. T. James, “Obesity,” The Lancet, vol. 366, no. 9492, pp. 1197–1209, 2005. View at Publisher · View at Google Scholar · View at Scopus
  30. E. M. Berke and N. E. Morden, “Medical management of obesity,” American Family Physician, vol. 62, no. 2, pp. 419–426, 2000. View at Google Scholar · View at Scopus
  31. F. Galtier, “Definition, epidemiology, risk factors,” Diabetes & Metabolism, vol. 36, no. 6, pp. 628–651, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. American Diabetes Association, “Diagnosis and classification of diabetes mellitus,” Diabetes Care, vol. 33, supplement 1, pp. S62–S69, 2010. View at Publisher · View at Google Scholar
  33. H. Sies, “Oxidative stress: oxidants and antioxidants,” Experimental Physiology, vol. 82, no. 2, pp. 291–295, 1997. View at Publisher · View at Google Scholar · View at Scopus
  34. M. J. Morgan and Z.-G. Liu, “Crosstalk of reactive oxygen species and NF-kappaB signaling,” Cell Research, vol. 21, no. 1, pp. 103–115, 2011. View at Publisher · View at Google Scholar · View at Scopus
  35. M. Naziroǧlu, N. Yoldaş, E. N. Uzgur, and M. Kayan, “Role of contrast media on oxidative stress, Ca2+ signaling and apoptosis in kidney,” Journal of Membrane Biology, vol. 246, no. 2, pp. 91–100, 2013. View at Publisher · View at Google Scholar · View at Scopus
  36. C. Maack and M. Böhm, “Targeting mitochondrial oxidative stress in heart failure: throttling the afterburner,” Journal of the American College of Cardiology, vol. 58, no. 1, pp. 83–86, 2011. View at Publisher · View at Google Scholar · View at Scopus
  37. Y. Lin, L. Bai, W. Chen, and S. Xu, “The NF-κB activation pathways, emerging molecular targets for cancer prevention and therapy,” Expert Opinion on Therapeutic Targets, vol. 14, no. 1, pp. 45–55, 2010. View at Publisher · View at Google Scholar · View at Scopus
  38. B. Kalyanaraman, “Teaching the basics of redox biology to medical and graduate students: oxidants, antioxidants and disease mechanisms,” Redox Biology, vol. 1, no. 1, pp. 244–257, 2013. View at Publisher · View at Google Scholar · View at Scopus
  39. C.-C. Sung, Y.-C. Hsu, C.-C. Chen, Y.-F. Lin, and C.-C. Wu, “Oxidative stress and nucleic acid oxidation in patients with chronic kidney disease,” Oxidative Medicine and Cellular Longevity, vol. 2013, Article ID 301982, 15 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  40. J. Arnhold, “Properties, functions, and secretion of human myeloperoxidase,” Biochemistry (Moscow), vol. 69, no. 1, pp. 4–9, 2004. View at Publisher · View at Google Scholar · View at Scopus
  41. E. P. Reeves, M. Nagl, J. Godovac-Zimmermann, and A. W. Segal, “Reassessment of the microbicidal activity of reactive oxygen species and hypochlorous acid with reference to the phagocytic vacuole of the neutrophil granulocyte,” Journal of Medical Microbiology, vol. 52, no. 8, pp. 643–651, 2003. View at Publisher · View at Google Scholar · View at Scopus
  42. J. Borawski, “Myeloperoxidase as a marker of hemodialysis biocompatibility and oxidative stress: the underestimated modifying effects of heparin,” The American Journal of Kidney Diseases, vol. 47, no. 1, pp. 37–41, 2006. View at Publisher · View at Google Scholar · View at Scopus
  43. E. Ho, K. Karimi Galougahi, C.-C. Liu, R. Bhindi, and G. A. Figtree, “Biological markers of oxidative stress: applications to cardiovascular research and practice,” Redox Biology, vol. 1, no. 1, pp. 483–491, 2013. View at Publisher · View at Google Scholar · View at Scopus
  44. M. C. Meuwese, E. S. G. Stroes, S. L. Hazen et al., “Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: the EPIC-Norfolk Prospective Population Study,” Journal of the American College of Cardiology, vol. 50, no. 2, pp. 159–165, 2007. View at Publisher · View at Google Scholar · View at Scopus
  45. M.-L. Brennan, M. S. Penn, F. Van Lente et al., “Prognostic value of myeloperoxidase in patients with chest pain,” The New England Journal of Medicine, vol. 349, no. 17, pp. 1595–1604, 2003. View at Publisher · View at Google Scholar · View at Scopus
  46. S. Baldus, C. Heeschen, T. Meinertz et al., “Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes,” Circulation, vol. 108, no. 12, pp. 1440–1445, 2003. View at Publisher · View at Google Scholar · View at Scopus
  47. Y. Maruyama, B. Lindholm, and P. Stenvinkel, “Inflammation and oxidative stress in ESRD—the role of myeloperoxidase,” Journal of Nephrology, vol. 17, supplement 8, pp. S72–S76, 2004. View at Google Scholar · View at Scopus
  48. D. Barra, F. Martini, J. V. Bannister et al., “The complete amino acid sequence of human Cu/Zn superoxide dismutase,” FEBS Letters, vol. 120, no. 1, pp. 53–56, 1980. View at Google Scholar · View at Scopus
  49. S. Shull, N. H. Heintz, M. Periasamy et al., “Differential regulation of antioxidant enzymes in response to oxidants,” The Journal of Biological Chemistry, vol. 266, no. 36, pp. 24398–24403, 1991. View at Google Scholar · View at Scopus
  50. S. I. Liochev and I. Fridovich, “Mechanism of the peroxidase activity of Cu, Zn superoxide dismutase,” Free Radical Biology and Medicine, vol. 48, no. 12, pp. 1565–1569, 2010. View at Publisher · View at Google Scholar · View at Scopus
  51. S. L. Acton, K. F. Kozarsky, and A. Rigotti, “The HDL receptor SR-BI: a new therapeutic target for atherosclerosis?” Molecular Medicine Today, vol. 5, no. 12, pp. 518–524, 1999. View at Publisher · View at Google Scholar · View at Scopus
  52. N. Abate, “Obesity and cardiovascular disease: pathogenetic role of the metabolic syndrome and therapeutic implications,” Journal of Diabetes and Its Complications, vol. 14, no. 3, pp. 154–174, 2000. View at Publisher · View at Google Scholar · View at Scopus
  53. S. Yamashita, K.-I. Hirano, N. Sakai, and Y. Matsuzawa, “Molecular biology and pathophysiological aspects of plasma cholesteryl ester transfer protein,” Biochimica et Biophysica Act—Molecular and Cell Biology of Lipids, vol. 1529, no. 1–3, pp. 257–275, 2000. View at Publisher · View at Google Scholar · View at Scopus
  54. U. Beisiegel, “New aspects on the role of plasma lipases in lipoprotein catabolism and atherosclerosis,” Atherosclerosis, vol. 124, no. 1, pp. 1–8, 1996. View at Publisher · View at Google Scholar · View at Scopus
  55. A. Zambon, J. E. Hokanson, B. G. Brown, and J. D. Brunzell, “Evidence for a new pathophysiological mechanism for coronary artery disease regression. Hepatic lipase-mediated changes in LDL density,” Circulation, vol. 99, no. 15, pp. 1959–1964, 1999. View at Publisher · View at Google Scholar · View at Scopus
  56. J.-G. Park and G. T. Oh, “The role of peroxidases in the pathogenesis of atherosclerosis,” BMB Reports, vol. 44, no. 8, pp. 497–505, 2011. View at Publisher · View at Google Scholar · View at Scopus
  57. M. Beer, T. Seyfarth, J. Sandstede et al., “Absolute concentrations of high-energy phosphate metabolites in normal, hypertrophied, and failing human myocardium measured noninvasively with 31P-SLOOP magnetic resonance spectroscopy,” Journal of the American College of Cardiology, vol. 40, no. 7, pp. 1267–1274, 2002. View at Publisher · View at Google Scholar · View at Scopus
  58. M. A. Conway, J. Allis, R. Ouwerkerk, T. Niioka, B. Rajagopalan, and G. K. Radda, “Detection of low phosphocreatine to ATP ratio in failing hypertrophied human myocardium by 31P magnetic resonance spectroscopy,” The Lancet, vol. 338, no. 8773, pp. 973–976, 1991. View at Publisher · View at Google Scholar · View at Scopus
  59. R. Tian, L. Nascimben, R. Kaddurah-Daouk, and J. S. Ingwall, “Depletion of energy reserve via the creatine kinase reaction during the evolution of heart failure in cardiomyopathic hamsters,” Journal of Molecular and Cellular Cardiology, vol. 28, no. 4, pp. 755–765, 1996. View at Publisher · View at Google Scholar · View at Scopus
  60. T. Kato, S. Niizuma, Y. Inuzuka et al., “Analysis of metabolic remodeling in compensated left ventricular hypertrophy and heart failure,” Circulation: Heart Failure, vol. 3, no. 3, pp. 420–430, 2010. View at Publisher · View at Google Scholar · View at Scopus
  61. B. Lei, V. Lionetti, M. E. Young et al., “Paradoxical downregulation of the glucose oxidation pathway despite enhanced flux in severe heart failure,” Journal of Molecular and Cellular Cardiology, vol. 36, no. 4, pp. 567–576, 2004. View at Publisher · View at Google Scholar · View at Scopus
  62. A. D. Hafstad, A. A. Nabeebaccus, and A. M. Shah, “Novel aspects of ROS signalling in heart failure,” Basic Research in Cardiology, vol. 108, no. 4, article no. 359, 2013. View at Publisher · View at Google Scholar · View at Scopus
  63. J. Marín-García, A. T. Akhmedov, and G. W. Moe, “Mitochondria in heart failure: the emerging role of mitochondrial dynamics,” Heart Failure Reviews, vol. 18, no. 4, pp. 439–456, 2013. View at Publisher · View at Google Scholar · View at Scopus
  64. T. Chabrashvili, A. Tojo, M. L. Onozato et al., “Expression and cellular localization of classic NADPH oxidase subunits in the spontaneously hypertensive rat kidney,” Hypertension, vol. 39, no. 2 I, pp. 269–274, 2002. View at Publisher · View at Google Scholar · View at Scopus
  65. A.-P. Zou, N. Li, and A. W. Cowley Jr., “Production and actions of superoxide in the renal medulla,” Hypertension, vol. 37, no. 2, pp. 547–553, 2001. View at Publisher · View at Google Scholar · View at Scopus
  66. L. Raij, “Nitric oxide and cardiovascular and renal effects,” Osteoarthritis and Cartilage, vol. 16, no. 2, pp. S21–S26, 2008. View at Publisher · View at Google Scholar · View at Scopus
  67. M. S. Ola, D. A. Berkich, Y. Xu et al., “Analysis of glucose metabolism in diabetic rat retinas,” The American Journal of Physiology—Endocrinology and Metabolism, vol. 290, no. 6, pp. E1057–E1067, 2006. View at Publisher · View at Google Scholar · View at Scopus
  68. T. Tiganis, “Reactive oxygen species and insulin resistance: the good, the bad and the ugly,” Trends in Pharmacological Sciences, vol. 32, no. 2, pp. 82–89, 2011. View at Publisher · View at Google Scholar · View at Scopus
  69. M. J. Burne-Taney and H. Rabb, “The role of adhesion molecules and T cells in ischemic renal injury,” Current Opinion in Nephrology and Hypertension, vol. 12, no. 1, pp. 85–90, 2003. View at Publisher · View at Google Scholar · View at Scopus
  70. C. Y. Goh, G. Vizzi, M. De Cal, and C. Ronco, “Cardiorenal syndrome: a complex series of combined heart/kidney disorders,” Contributions to Nephrology, vol. 174, pp. 33–45, 2011. View at Publisher · View at Google Scholar · View at Scopus
  71. M. H. Rosner, C. Ronco, and M. D. Okusa, “The role of inflammation in the cardio-renal syndrome: a focus on cytokines and inflammatory mediators,” Seminars in Nephrology, vol. 32, no. 1, pp. 70–78, 2012. View at Publisher · View at Google Scholar · View at Scopus
  72. G. M. Virzì, R. Torregrossa, D. N. Cruz et al., “Cardiorenal syndrome type 1 may be immunologically mediated: a pilot evaluation of monocyte apoptosis,” Cardiorenal Medicine, vol. 2, no. 1, pp. 33–42, 2012. View at Publisher · View at Google Scholar
  73. M. L. Kielar, R. John, M. Bennett et al., “Maladaptive role of IL-6 in ischemic acute renal failure,” Journal of the American Society of Nephrology, vol. 16, no. 11, pp. 3315–3325, 2005. View at Publisher · View at Google Scholar · View at Scopus
  74. H. Rabb, “Immune modulation of acute kidney injury,” Journal of the American Society of Nephrology, vol. 17, no. 3, pp. 604–606, 2006. View at Publisher · View at Google Scholar · View at Scopus
  75. G. Ramesh and W. B. Reeves, “Inflammatory cytokines in acute renal failure,” Kidney International, vol. 66, no. 91, pp. S56–S61, 2004. View at Google Scholar · View at Scopus